HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ethmozine for ventricular premature complexes.

Abstract
Twenty patients with an average of more than 30 ventricular premature complexes (VPCs) per hour were treated with ethmozine. Eighteen had either not responded or had adverse reactions to at least 1 other antiarrhythmic drug. Patients were treated with 200 to 300 mg 3 times daily (8.25 to 11.7 mg/kg) and were followed for up to 6 months. Three patients were withdrawn from ethmozine therapy because of unwanted effects before evaluation of efficacy. One of these patients had sustained ventricular tachycardia (VT) after a loading dose of ethmozine. Eleven of the remaining 17 patients (65%) experienced more than a 75% reduction in ventricular ectopic activity. Six patients had a smaller or no decrease in VPC frequency. Eleven of 16 patients (68%) with paired VPCs had a more than 90% reduction in paired VPC frequency. Eleven of 13 patients (84%) with VT events of 3 beats or more had more than a 90% reduction in VT events. Of the 11 patients in whom a more than 75% reduction in VPC frequency occurred, 1 patient died suddenly after 133 days of effective drug therapy. Three patients discontinued ethmozine therapy for reasons not related to the drug. Of the 6 patients in whom there was less than a 75% reduction in VPC frequency, 2 patients discontinued treatment, 1 patient because of hyperanxiety and 1 because of drug-related left anterior hemiblock. Ethmozine lengthened PR and QRS intervals but not the JT interval. Thus, ethmozine is effective and clinically useful for suppression of frequency VPCs in 50% (10 of 20 patients) of a selected population.
AuthorsK Gear, F I Marcus, S K Huang, P E Fenster, C Appleton, V Moeller, G Renaud, R Serokman
JournalThe American journal of cardiology (Am J Cardiol) Vol. 57 Issue 11 Pg. 947-9 (Apr 15 1986) ISSN: 0002-9149 [Print] United States
PMID2421571 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Arrhythmia Agents
  • Phenothiazines
  • Placebos
  • Moricizine
Topics
  • Aged
  • Anti-Arrhythmia Agents (administration & dosage, adverse effects, therapeutic use)
  • Cardiac Complexes, Premature (drug therapy)
  • Clinical Trials as Topic
  • Electrocardiography
  • Female
  • Heart Ventricles (physiopathology)
  • Humans
  • Male
  • Middle Aged
  • Moricizine
  • Phenothiazines (administration & dosage, adverse effects, therapeutic use)
  • Placebos
  • Tachycardia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: